Söndag 22 December | 04:45:49 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-02-21 08:30 Bokslutskommuniké 2024
2024-08-23 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-04-19 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2024-02-23 - Bokslutskommuniké 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-04-20 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2023-04-19 - Årsstämma
2023-02-24 - Bokslutskommuniké 2022
2023-02-17 - Bokslutskommuniké 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-08-17 - Kvartalsrapport 2022-Q2
2022-06-10 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2022-04-20 - Årsstämma
2022-02-25 - Bokslutskommuniké 2021
2021-08-27 - Kvartalsrapport 2021-Q2
2021-06-04 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2021-06-03 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-08-25 - Kvartalsrapport 2020-Q2
2020-02-27 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2020-02-26 - Årsstämma
2020-02-04 - Bokslutskommuniké 2019
2019-05-08 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2019-05-07 - Årsstämma
2019-02-22 - Bokslutskommuniké 2018
2018-08-10 - Kvartalsrapport 2018-Q2
2018-05-03 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2018-05-02 - Årsstämma
2018-02-23 - Bokslutskommuniké 2017
2017-08-11 - Kvartalsrapport 2017-Q2
2017-03-21 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2017-03-20 - Årsstämma
2017-02-17 - Bokslutskommuniké 2016
2016-11-04 - Kvartalsrapport 2016-Q3
2016-08-04 - Kvartalsrapport 2016-Q2
2016-05-04 - X-dag ordinarie utdelning CLINE B 0.00 SEK
2016-05-03 - Kvartalsrapport 2016-Q1
2015-11-06 - Kvartalsrapport 2015-Q3
2015-08-06 - Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Cline Scientific är verksamt inom bioteknik. Bolaget är specialiserat inom cancerdiagnostik och stamcellsterapier. Bolaget genomför utvecklingsprojekt via samarbeten med forskningsinstitutioner, där teknologin används i cellbaserade produkter och processer för att driva Life Science projekt till och genom den kliniska fasen. Bolaget har sitt huvudkontor i Göteborg och grundades under 2012.
2024-03-01 08:30:00

Cline Scientific AB (publ) ("Cline" or the "Company") last three experimental campaigns show successful results in measures of initial cell dose and important time aspects.

During the autumn, Cline, as previously communicated, carried out three major experimental campaigns in the StemCART project. These aimed to arrive at a suitable starting dose of chondrocyte cells to initiate a clear regeneration of the cartilage tissue. Cells grown according to Cline's method and matrix were placed within a controlled injury made in cartilage tissue removed from knee joints. The goal was to test various doses from a few tens of thousands to several million cells. The campaigns resulted in finding a suitable initial dose for cartilage regeneration for this type of injury. The extent of regeneration was analyzed on several occasions within 8 weeks and the desired regeneration result was achieved. These results consist of factors such as visible formation of tissues, gene expression and cell viability, among other. Thus, this milestone has been achieved.

As the next step, Cline is planning to combine cells and the matrix in 3D configuration before implantation. This is to simplify implantation as well as both streamline and shorten the process between cell cultivation and implantation.

"The results of the last year's work show that our original plan is relevant in that the set goals are achieved. We feel confident in continuing with our plan to move step by step towards a Phase I clinical trial." Hanne Evenbratt VP of R&D.